Arcus Biosciences/$RCUS
1D1W1MYTD1Y5YMAX
Capital at risk
About Arcus Biosciences
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
- Ticker
- $RCUS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 601
- Headquarters
- Hayward, United States
- Website
- arcusbio.com
RCUS Metrics
BasicAdvanced
$3.4B
-
-$3.86
0.81
-
Price and volume
Market cap
$3.4B
Beta
0.81
52-week high
$31.74
52-week low
$12.15
Average daily volume
1.5M
Financial strength
Current ratio
3.818
Quick ratio
3.753
Long term debt to equity
0.485
Total debt to equity
0.513
Interest coverage (TTM)
-44.18%
Profitability
EBITDA (TTM)
-476
Gross margin (TTM)
-324.79%
Net profit margin (TTM)
-393.16%
Operating margin (TTM)
-415.38%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-30.39%
Return on equity (TTM)
-90.82%
Valuation
Price to revenue (TTM)
27.352
Price to book
7.35
Price to tangible book (TTM)
7.35
Price to free cash flow (TTM)
-6.737
Free cash flow yield (TTM)
-14.84%
Free cash flow per share (TTM)
-3.988
Growth
Revenue change (TTM)
-55.34%
Earnings per share change (TTM)
25.71%
3-year revenue growth (CAGR)
-1.11%
3-year earnings per share growth (CAGR)
-0.68%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
Analyst projections of the future price of Arcus Biosciences stock.
Bulls say / Bears say
Casdatifan has generated substantial strategic momentum in 2026, with Arcus advancing multiple collaborations covering combinations with BMS’s pumitamig, Summit’s ivonescimab and AVEO’s tivozanib across kidney-cancer settings. These partnerships expand the potential treatment combinations and provide external validation of the program’s relevance. (Arcus Biosciences; Arcus Biosciences)
Arcus expects several casdatifan readouts in the second half of 2026, including first-line efficacy, second-line progression-free survival and late-line overall-survival data. Multiple near-term catalysts could materially clarify the drug’s commercial and regulatory potential. (Arcus Biosciences)
The company reported $775 million in cash, cash equivalents and marketable securities at June 30, 2026, with a projected runway until at least the second half of 2028. That liquidity gives Arcus time to fund pivotal casdatifan development while also advancing its wholly owned inflammation portfolio, including AB102’s expected 2026 clinical entry. (Arcus Biosciences)
Arcus discontinued the Phase 3 STAR-121 study in April 2026 after a pre-planned futility analysis found the domvanalimab-based regimen was not improving overall survival versus pembrolizumab plus chemotherapy, removing a major late-stage lung-cancer opportunity. (Arcus Biosciences)
The investment case is increasingly concentrated in casdatifan: Arcus has prioritized the kidney-cancer program after setbacks in other oncology assets, while the key first-line and combination studies remain investigational and data-dependent. (Arcus Biosciences)
Cash and investments declined from $876 million at March 31, 2026 to $775 million at June 30, 2026, highlighting continued cash burn before any product reaches commercialization; the company remains dependent on its stated runway and future clinical execution. (Arcus Biosciences; Arcus Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
Upcoming events
No upcoming events
RCUS News
AllArticlesVideos
Funds containing RCUS
AllUSDEURGBP
Fund name | Fund size | $RCUS weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.23% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.23% |
iShares Healthcare Innovation£DRDR | £1B | 0.23% |
iShares Ageing Population€AGED | €822M | 0.20% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.